Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children

Figures & data

Table 1. Characteristics of the study population

Characteristic	Study population N (%)	Carriage period prevalence N (% among participants with that characteristic)	p-value
Age 60–69 y 70–79 y ≥ 80 y	43 (15.2) 164 (57.9) 76 (26.9)	8 (18.6) 40 (24.4) 8 (10.5)	0.042
Cohabiting adults Yes No	223 (78.8) 60 (21.2)	45 (20.2) 11 (18.3)	NS
Smoker Yes No	45 (15.9) 238 (84.1)	8 (17.8) 48 (20.2)	NS
Passive smoke Yes No	36 (12.8) 246 (87.2)	7 (19.4) 49 (19.9)	NS
Frequent contacts with children Yes No	66 (23.3) 217 (76.7)	22 (33.3) 34 (15.7)	0.003
Frequent contacts with children attending day care Yes No	59 (20.9) 223 (79.1)	19 (32.2) 37 (16.6)	0.01
Chronic cardiovascular disease Yes No	121 (42.9) 161 (57.1)	22 (18.1) 34 (21.1)	NS
Chronic respiratory disease Yes No	43 (15.3) 239 (84.8)	8 (18.6) 48 (20.1)	NS
Diabetes Yes No	57 (20.2) 225 (79.8)	12 (21.1) 44 (19.6)	NS
Cancer Yes No	33 (11.7) 249 (88.3)	7 (21.2) 49 (19.7)	NS
Respiratory infection Yes No	64 (22.7) 218 (77.3)	14 (21.9) 42 (19.3)	NS
Antimicrobial drug Yes No	75 (26.6) 207 (73.4)	15 (20) 41 (19.8)	NS
PPV23 vaccination Yes No	40 (14.2) 242 (85.8)	5 (12.5) 51 (21.1)	NS

Figure 1. Proportion of children colonized with different serotypes, after adjustment for age. *The serotype 6B primer set used in the study and recommended by CDC was also cross-reactive with the common serotype 6A cps operon sequence. #PCV7 and PPV23 do not include serotype 6A

Figure 2. Bivariate fit of prevalence of the 15 most prevalent serotypes observed in adults aged 60 y or over by that observed in children younger than 5 y, which emerged in previous study performed in the autumn of 2010.